GlassScriptPhysician profile
Vinay Antin
NPI 1316224116
$6,786.10
in general payments reported to CMS, 2019-2025
34 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $320 · 2021: $781 · 2022: $685 · 2023: $1,218 · 2024: $1,513 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,362 · Education: $77.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,361.71 |
| Education | $77.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,266.01 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $531.29 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $498.36 | 2019-2025 | Entyvio |
| Celgene Corporation | $376.88 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $259.87 | 2019-2025 | Stelara, Simponi, Remicade |
| Lilly USA, LLC | $202.55 | 2023-2025 | Omvoh |
| Pfizer INC. | $193.18 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $141.79 | 2025 | Iqirvo |
| Qol Medical, LLC | $140.24 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $133.25 | 2021-2025 | Ocaliva |
| Boston Scientific Corporation | $118.42 | 2019 | |
| Redhill Biopharma INC. | $116.54 | 2020-2023 | Talicia |
| Celltrion USA INC. | $88.99 | 2024-2025 | Zymfentra, Vegzelma |
| Enterra Medical, INC. | $85.14 | 2024-2025 | |
| Shionogi INC | $62.55 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $59.71 | 2022-2024 | Ibsrela |
| Allergan, INC. | $56.20 | 2019 | |
| Gilead Sciences, INC. | $52.99 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $51.58 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $42.44 | 2020-2023 | Dificid |
| Madrigal Pharmaceuticals | $42.20 | 2024-2025 | Resmetirom, Rezdiffra |
| Phathom Pharmaceuticals, INC. | $38.92 | 2025 | Voquezna |
| Ethicon US, LLC | $35.77 | 2019 | |
| Vivus LLC | $30.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.63 | 2019 | |
| Braintree Laboratories, INC. | $25.51 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Novo Nordisk INC | $19.53 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $17.16 | 2019 | |
| Pharmacosmos Therapeutics INC. | $16.53 | 2021 | |
| Fresenius Kabi USA, LLC | $14.04 | 2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $13.71 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $3.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,433.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Antin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.